Nivolumab + Ipilimumab

Combination dosing guide^#

1L metastatic/recurrent NSCLC (with chemo)

1L unresectable malignant pleural mesothelioma

1L advanced ccRCC^*

1L+ advanced HCC

Metastatic/unresectable melanoma

1L+ MSI-H/d-MMR metastatic/recurrent CRC

1L unresectable advanced/recurrent/ metastatic ESCC

^#This guide is for scientific education purposes only in response to your enquires/request. For further enquiries, please contact your local BMS Medical Science Liaison or contact BMS Medical Information Department at medinfo.hongkong@bms.com.

^*Nivolumab in combination with ipilimumab is only approved for 1L ccRCC patients with an intermediate or poor risk profile.

1L, first-line; 2L+, second-line or later; ccRCC, clear cell renal cell carcinoma; CRC, colorectal cancer; d-MMR, mismatch repair deficient; ESCC, esophageal squamous cell carcinoma; FDA, US Food and Drug Administration; HCC, hepatocellular carcinoma; MSI-H, high microsatellite instability; NSCLC, non-small cell lung cancer.